Capricor Therapeutics
Business Services · California, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
10865 Road to the Cure Ste 150, San Dieg...Phone Number
(858) 727-1755Website
www.capricor.comRevenue
$11.1 MillionStock Symbol
CAPRIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Capricor Therapeutics
Capricor Therapeutics is a biotechnology company focused on developing innovative therapies designed to make a meaningful impact on patients’ lives. The company specializes in biologics, with a primary focus on cell- and exosome-based technologies for the treatment and prevention of a broad range of diseases. Capricor aims to advance transformative therapeutic approaches by leveraging its expertise in regenerative medicine, cellular therapies, and exosome technology to address significant unmet medical needs.Explore more
Capricor Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Capricor Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Capricor Therapeutics has new funding data
Capricor Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Capricor Therapeutics
Click to see if Capricor Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Capricor Therapeutics launches new products
Check out if Capricor Therapeutics is spiking on competitors!
Check if Capricor Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Capricor Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Capricor Therapeutics as Masked Content
Find 3 more new buyers
Compare Similar Companies to Capricor Therapeutics
Compare insights from companies similar to Capricor Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$196.1M
201-500
Public
$466M
1990
Bryan RidgellSenior Vice President, Portfolio and Project Management, and Chief of Staff
Company Profile Activity
Activity Insights
Capricor Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Capricor Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Capricor Therapeutics.
Capricor Therapeutics financials insights
Gather financial insights about Capricor Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$150K
2024
Private Equity
$35M
Capricor Therapeutics Tech Stack
A closer look at the technologies used by Capricor Therapeutics
See more technologies
Most Recent Scoops
Facilities Relocation / Expansion
Facilities Relocation/Expansion, Leasing, Manufacturing Operations
Person-Based
Stake & Stock Ownership, Finance
Open Position
Open Position
Open Position
Capricor Therapeutics News & Media
CAPR Shareholder Alert: Capricor Therapeutics, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky
A securities class action alleges Capricor Therapeutics failed to disclose that it changed the pre-specified statistical analysis plan for its Phase 3 HOPE-3 trial without FDA agreement, leaving results the agency characterized as "post-hoc and exploratory." NEW YORK, Aug. 26, 2026...SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Capricor Therapeutics, Inc. (CAPR)
Capricor Therapeutics Shareholders Between December 17, 2025 and July 6, 2026 - Contact Bernstein Liebhard For More Information Regarding LawsuitLead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Rackspace Technology, Inc. (RXT), Capricor Therapeutics, Inc. (CAPR), and Wise Group plc (WSE) Announced by Holzer & Holzer, LLC
ATLANTA, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC reminds investors of the deadline to seek to be appointed lead plaintiff in the following class action lawsuits:CAPR Securities Notice: Lose Money on Your Capricor Therapeutics Investment? BFA Law Notifies Investors of the Pending Securities Fraud Class Action to Recover Losses
Lose Money on Your Capricor Therapeutics Investment? BFA Law Notifies Investors of the Pending Securities Fraud Class Action to Recover Losses
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Capricor Therapeutics
Sign Up For FreeTo access detailed company insights
Capricor Therapeutics is a biotechnology company focused on developing innovative therapies designed to make a meaningful impact on patients’ lives. The company specializes in biologics, with a primary focus on cell- and exosome-based technologies for the treatment and prevention of a broad range of diseases. Capricor aims to advance transformative... Read More
